CandlesenseCandlesense
News/Companies/GCTK

GCTK News

Glucotrack to Participate in the Q3 Virtual Investor Summit

GCTK

(NASDAQ:GCTK) RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that management will present and participate in one-on-one meetings with investors at the Q3 Virtual Investor Summit, being held on September 16-17, 2025.

September 11, 2025Investor
Read more →

Glucotrack To Effect 1-for-60 Reverse Stock Split, Effective At Opening Of Trading Jun. 16

GCTK

June 12, 2025
Read more →

GlucoTrack Forms Patient Advisory Board Of Leading Diabetes Advocates To Incorporate Patient Insights Into Development Of Long-Term Implantable Continuous Blood Glucose Monitor

GCTK

May 20, 2025
Read more →

Glucotrack Receives Ethical Approval From St. Vincent's Hospital Melbourne Human Research Ethics Committee For Long-Term Clinical Study of Continuous Blood Glucose Monitor

GCTK

May 13, 2025
Read more →

Glucotrack Secures Ethical Approval From St. Vincent's Hospital Melbourne HREC For Long-Term Clinical Study Of CBGM In Participants With Type 1 And Type 2 Diabetes

GCTK

May 13, 2025
Read more →

Glucotrack Announces Safety And Performance Data From Its First-In-Human Trial Of Its Long-Term Continuous Blood Glucose Monitoring System Will Be Presented At The 2025 International Conference On ATTD March 19 – 22, 2025

GCTK

March 19, 2025
Read more →

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

GCTK

May 17, 2024
Read more →